TNYA Earnings Date: Nov 11, 2026 (Estimated) — Tenaya Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is TNYA's next earnings date?
Tenaya Therapeutics, Inc. (TNYA) is expected to report earnings on Wednesday, November 11, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.10 on revenue of $800,000.
How did TNYA do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Tenaya Therapeutics, Inc. posted EPS of -$0.20 versus the -$0.07 estimate, a miss of 185.7%. Revenue was $1.1M against a $10.0M estimate. The stock's 1-day post-earnings move was -7.5%.
How much does TNYA stock move after earnings?
TNYA beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.1% (up or down) in the day after earnings.
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.07 | -0.20 | -185.71% | $1.1M | ❌ Miss | -7.51% | -2.70% | -11.39% |
| 2026-05-06 | Q1 2026 | -0.09 | -0.09 | +0.00% | $25.0M | ➖ Inline | +7.37% | +21.43% | -7.86% |
| 2026-03-11 | Q4 2025 | -0.12 | -0.12 | +0.00% | $0 | ➖ Inline | +3.98% | -4.22% | -19.65% |
| 2025-11-10 | Q3 2025 | -0.15 | -0.12 | +20.00% | $0 | ✅ Beat | +11.72% | +3.91% | +10.16% |
| 2025-08-06 | Q2 2025 | -0.19 | -0.14 | +26.32% | $0 | ✅ Beat | -1.69% | +27.65% | +100.12% |
| 2025-03-10 | Q4 2024 | -0.31 | -0.28 | +9.68% | $0 | ✅ Beat | +6.78% | +44.35% | -17.58% |
| 2024-05-14 | Q1 2024 | -0.42 | -0.40 | +4.76% | $0 | ✅ Beat | -3.41% | -5.00% | -15.00% |
| 2024-03-18 | Q4 2023 | -0.44 | -0.40 | +9.09% | $0 | ✅ Beat | -6.02% | +0.83% | -10.79% |
Showing last 8 quarters.